Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1463Pancreatic Neoplasms 833Stomach Neoplasms 692Carcinoma, Hepatocellular 647Carcinoma, Non-Small-Cell Lung 542Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 337Colonic Neoplasms 332Esophageal Neoplasms 297Liver Neoplasms 266Melanoma 255Lung Neoplasms 246Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 180Carcinoma, Renal Cell 180Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 163Rectal Neoplasms 160Endometrial Neoplasms 160Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 135Gastrointestinal Stromal Tumors 108Sarcoma 105Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2-Positive Advanced Biliary Tract Cancer × Gastrointestinal × Clear all
NCT04578444 2025-05-25

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Jazz Pharmaceuticals

No longer available
Gastrointestinal

HER2-Positive Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡